Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Plans For Soy Health Claims, Pyridoxamine's Use Questioned By CRN, NPA

Executive Summary

FDA’s proposed rule to revoke soy protein heart health ignores research supporting the claims and cites evidence that isn't compelling, CRN an NPA say in comments to the agency. CRN also submits comments supporting an ingredient firm's petition asking FDA to remove any uncertainty about the of use of pyridoxamine as a dietary ingredient.

Advertisement

Related Content

Pyridoxamine Petition Paints Better Option As Dietary Ingredient Than IND
FDA Doubts 'Certainty' Of Soy Heart Benefit In First Health Claim Revocation
Industry Eyes NDI Notification Common Ground With Gottlieb-Led FDA
FDA Touches Constitutional Nerve In Warning On Mixing Supplements, Drugs – NPA

Topics

Advertisement
UsernamePublicRestriction

Register

RS121524

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel